Author

David S. Millan

Foghorn Therapeutics (United States)ORCID 0000-0001-5590-7273Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Ammar Adam· 1 shared Carl P. Decicco· 1 shared David L. LahriD· 1 shared David S. HuangiD· 1 shared Gabriel J. Sandoval· 1 shared GiNell ElliottiD· 1 shared Gromoslaw Aleksander SmoleniD· 1 shared Ho Man ChaniD· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ammar Adam

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintSep 11, 2023

Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers

Richard C. Centore, Luis Miguel Mendes Soares, Salih Topal…·Steven F. Bellon

This study identifies and characterizes inhibitors of SMARCA4/SMARCA2 ATPases, showing their ability to induce lineage-specific chromatin changes and tumor regression in uveal melanoma.

8 citations

mouseChIP-seq

𝕏 PostBluesky